Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Gross Margin (2016 - 2026)

Pharma-Bio Serv's Gross Margin history spans 16 years, with the latest figure at 31.48% for Q1 2026.

  • For Q1 2026, Gross Margin rose 40.0% year-over-year to 31.48%; the TTM value through Jan 2026 reached 32.46%, up 383.0%, while the annual FY2025 figure was 32.33%, 587.0% up from the prior year.
  • Gross Margin reached 31.48% in Q1 2026 per PBSV's latest filing, down from 34.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 34.84% in Q4 2025 to a low of 22.5% in Q1 2024.
  • Average Gross Margin over 5 years is 28.56%, with a median of 29.25% recorded in 2025.
  • Peak YoY movement for Gross Margin: crashed -759bps in 2024, then surged 858bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 23.9% in 2022, then rose by 8bps to 25.84% in 2023, then increased by 21bps to 31.14% in 2024, then rose by 12bps to 34.84% in 2025, then decreased by -10bps to 31.48% in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Gross Margin are 31.48% (Q1 2026), 34.84% (Q4 2025), and 29.25% (Q3 2025).